AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01108653 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care sick-leave management
Description: Patients randomized to usual care. Follow up after discharge by general practitioner (GP) according to local practice.
Study NCT01108653 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Structuralised sick-leave program
Description: Patients randomized to the structuralized program will get full time sick-leave for 2 weeks after discharge.Cardiologist will be responsible for individual adaption of each patient's sick-leave and follow-up.
Study NCT04051372 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoscopic Alveolar Lavage
Description: The diagnostic yield of different diagnostic methods for lung infection and non-infectious diseases under allo-HSCT patients.~1. Classic microbiological cultures designed for bacteria, fungi, and mycobacteria.~2. Detection of human cytomegalovirus (CMV) and EB virus in serum and BAL was tested using a Real-time PCR kit.~3. Detection of aspergillus galactomannan antigen 1,3-beta-D-glucan in serum and BAL was performed using an enzyme immunoassay method.~4. Cytological and pathogenic microscopic evaluation in BALF~5. Flow cytological analysis of T lymphocyte subsets in BALF and serum~6. Cytokine detection in BALF and serum~7. Microbiology detection in BALF by mNGS
Study NCT02270606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT02270606 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo total mesorectal excision
Study NCT04163302 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-PD1-CART Cell
Description: This study was a single-center, open-label, single-arm, non-randomized clinical trial, which has 3 groups by infusion dose level. Firstly, each dose group has 3 patients. The pretreatment regimen of cyclophosphamide (25mg/m2 for 3 consecutive days) and fludarabine (10mg/kg for 3 consecutive days) was given before CART cells were reinfused. CART cells were reinfused on the third day after the pretreatment. If no serious side effects emerges in the group, then the next group uses the subsequent higher dose. If serious side effects emerges in a single patients in any dose level, 3 more patients will be enrolled to the same dose level. After 9 or more patients, the investigators select the safest dose and recruit more patients for CART test to explore its effectiveness.
Study NCT03079284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Holding during cooling
Description: An initial set of vital sings will be recorded before the infant is removed from the isolette. The mother will sit in a reclining chair next to the isolette and place a thermal barrier over her chest and abdomen. The infant will be transferred to the mother by placing the hands under the cooling blanket so as to move the infant and cooling blanket together as one unit. The mother will be allowed to hold for thirty minutes provided that the infant's temperature does not increase by greater than one degree centigrade and the oxygen saturation does not drop below 90%. After thirty minutes, the infant will be returned to the isolette.
Study NCT03572998 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Indocyanine Green (ICG)
Description: Injection of ICG as a fluorophore for Near Infrared fluorescence Imaging (NIRF)
Study NCT00591487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Subcutaneous infiltration with Active/Placebo solutions with tumescent technique previous to suction assisted lipectomy. Patient abdomen and back will be divided in 4 zones anterior and posterior, one side (left or right) will be infiltrated with active solution and the other with placebo. The allocation of the side will be made with random numbers.
Study NCT00591487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: Subcutaneous infiltration with Active/Placebo solutions with tumescent technique previous to suction assisted lipectomy. Patient abdomen and back will be divided in 4 zones anterior and posterior, one side (left or right) will be infiltrated with active solution and the other with placebo. The allocation of the side will be made with random numbers.
Study NCT01899846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyprogesterone caproate 250 mg/ml
Study NCT00288587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV loop diuretic
Description: Use of conventional diuretic therapy upon hospital admission for treatment of decompensated heart failure.
Study NCT00288587 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NxStage System One
Description: Patients treated with Extracorporeal Ultrafiltration upon hospital admission for treatment of decompensated heart failure.
Study NCT04000828 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Placement of Sensimed Triggerfish
Description: Sensimed Triggerfish is placed on the corneal surface
Study NCT04162392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: shared decision making
Description: Patients can choose the intervention that they want. There are different physiotherapy interventions were the patients have to do physical activity during the hospital stay. The physiotherapist explains the advantages and disadvantages of each treatment before they choose.
Study NCT04162392 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: Patients receive a physiotherapy intervention but they do not have the opportunity to choose the treatment
Study NCT00875836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: Flexible dose, up to 60 mg daily
Study NCT00875836 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Flexible dose, up to 60 mg daily
Study NCT00002484 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT00823459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO
Study NCT00823459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Archival Tissue Analysis
Description: Correlative studies
Study NCT04226924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trehalose
Description: 90 mg/ml trehalose solution for IV infusion
Study NCT04226924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trehalose
Description: 90 mg/ml trehalose solution for IV infusion
Study NCT05472428 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell transplantation
Description: Transplantation of Autologous Bone Marrow Mononuclear cells
Study NCT05465889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral sulfate solution (OSS)
Description: OSS contained 17.5 g sodium sulfate, 3.13 g potassium sulfate, 1.6 g magnesium sulfate, and flavoring agents in an aqueous liquid form supplied in a 177 mL bottle. Take 177ml sodium, potassium and magnesium sulfates oral solution (diluted to 480ml) within 30 minutes 14-16 hours before colonoscopy, followed by two doses of 480ml warm water within 1 hour; Repeat the procedure 3-4 hours before colonoscopy.
Study NCT05465889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol Electrolyte
Description: Take 1000 ml polyethylene glycol electrolyte solution within 1 hour at 8 p.m. the day before colonoscopy; take 2000 ml polyethylene glycol electrolyte solution within 2 hour 4-6 hours before colonoscopy.
Study NCT04305925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focal Laser Ablation
Description: Orion system to deploy and monitor thermal energy in cancerous regions of the prostate, identified by MRI and confirmed by targeted biopsy. MRI guidance will be achieved by MRI/ultrasound fusion, overlaying stored MRI images upon real-time ultrasound images. Interstitial laser treatments would be achieved by inserting the fiber into the cancerous regions guided by the Artemis image-fusion device. Applications of laser energy up to 15 watts of power will be used to treat the target region.
Study NCT00856050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Taken orally once a day continuously
Study NCT05246423 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Observation group
Description: Patients with paroxysmal atrial fibrillation undergo cardiopulmonary exercise testing, echocardiography, 24-hour ambulatory electrocardiographic monitoring and plasma biomarkers' measurement
Study NCT03910127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study NCT03910127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQB2450
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study NCT03910127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: a multi-target receptor tyrosine kinase inhibitor
Study NCT03910127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anlotinib
Description: matching placebo
Study NCT01657422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACE+
Description: Patients assigned to the intervention group will receive intervention strategies over a the course of 2 years including: (1) completion of a 45-minute office-based computer program resulting in an assessment and action plan for improvement in physical activity and nutrition behaviors; (2) a provider counseling session immediately following the computerized assessment, followed by (3) 12 phone calls and 24 mailings over a 24-month period conducted by PACE+ staff members
Study NCT01253434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2022
Description: E2022 Type A patch
Study NCT01253434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2022
Description: E2022 Type B patch
Study NCT01253434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2022
Description: E2022 Type C patch
Study NCT01253434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2022
Description: E2022 Type D patch
Study NCT01253434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2022
Description: E2022 Type E patch
Study NCT00690521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of Furosemide + Hydrochlorothiazide
Description: A randomized, double-blind, crossover study designed to compare the efficacy of hydrochlorothiazide in combination with stable doses of furosemide in congestive heart failure patients.
Study NCT00690521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of Furosemide + Metolazone
Description: A randomized, double-blind, crossover study designed to compare the efficacy of metolazone in combination with stable doses of furosemide in congestive heart failure patients.
Study NCT03225092 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided platelet rich plasma injection
Description: Each participant will receive a single injection into the pes anserine bursa (using the Arthrex Angel system with a setting of 180cc of peripheral blood and 1% hematocrit concentration) under sterile technique
Study NCT00972114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CABG combined cardiomyoplasty
Description: coronary artery bypass graft surgery combined pedicled omentum wrapped autologous atrial tissue patch cardiomyoplasty
Study NCT00972114 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG combined pedicled omentum graft
Description: Coronary artery bypass graft surgery combined pedicled omentum graft
Study NCT00972114 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG alone
Description: Coronary artery bypass graft surgery alone
Study NCT02658032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: personalized cessation care
Description: Individuals randomized to this condition will receive standard care (i.e., 5 counseling sessions and nicotine patch(NRT)) and 4 personalized videos with 5 packages of personalized print materials
Study NCT02658032 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: personalized cessation care
Description: Individuals randomized to this condition will receive standard care (i.e., 5 counseling sessions and nicotine patch(NRT)) and 4 personalized videos with 5 packages of personalized print materials
Study NCT02658032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: bio feedback
Description: Individuals randomized to this group will be provided with a personalized graph of their biomarker data from baseline, 6 and 8 weeks at the 8-week and 3-month study visits.
Study NCT02658032 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: bio feedback
Description: Individuals randomized to this group will be provided with a personalized graph of their biomarker data from baseline, 6 and 8 weeks at the 8-week and 3-month study visits.
Study NCT02658032 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standard care
Study NCT00147745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam
Description: Colesevelam 3.8g for 12 weeks
Study NCT00147745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colesevelam matching placebo
Description: Colesevelam matching placebo for 12 weeks
Study NCT00147745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine (Lantus)
Description: Insulin glargine for 12 weeks
Study NCT03966014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EM-amoxicillin 3 x 10 days
Description: Patients will receive amoxicillin 500 milligram tid for 10 days
Study NCT03966014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EM-amoxicillin 3 x 14 days
Description: Patients will receive amoxicillin 500 milligram tid for 14 days
Study NCT03966014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EM-amoxicillin 2 x 14 days
Description: Patients will receive amoxicillin 500 milligram bid for 14 days
Study NCT03966014 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Controls
Description: No intervention.
Study NCT01901302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-5945
Study NCT01901302 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05682040 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Bedside Compression Ultrasonography
Description: Point of Care Ultrasound (Bedside Compression Ultrasonography) vs formal lower extremity Doppler
Study NCT04639076 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Weight Loss Program
Description: The BWL group will receive a standard weight loss intervention based on the evidence-based interventions currently being recommended for clinical practice, with general recommendations for caloric reductions based on starting weight and progressive weekly increases of physical activity (PA). Supporting behavioral lessons based on materials used in the Diabetes Prevention Program (DPP) will also be delivered. The weight loss 'prescription' will remain consistent throughout the 3 month trial. Participants will receive digital tools including a study smart phone app that incorporates diet self-monitoring, tracking of behavioral goals, behavioral lessons and resources, and integration of data from a study-provided Wi-Fi enabled scale and physical activity tracker.
Study NCT04639076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Behavioral Weight Loss Program
Description: The PBWL group will receive a calorie goal based on measured resting energy expenditure and baseline PA. In Weeks 1-4, participants will be randomly assigned to test patterns that manipulate diet composition (low-fat or low-carbohydrate), meal frequency (3 or 5-6 meals/day), and PA goals (weekly minutes or daily minutes goals). Following this period, the optimal combination will be identified by the participant and interventionist, based on weight loss, blood glucose, hunger and ability to adhere to the prescription. This group will receive the same supporting behavioral lessons as the BWL group along with additional resources specific to their personalized prescription. The weight loss 'prescription' will vary across the 3-month trial based on response to treatment. Participants will receive the same digital tools as the BWL group with resources specific to following the prescription they are following during any given program week.
Study NCT01757171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: 20mg IV over 1 hour every 3 weeks
Study NCT03151161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib,Pemetrexed,Carboplatin
Description: Pemetrexed (500mg/m2) + Carboplatin (AUC=5), every 3 weeks, maximum 4 cycles; icotinib 125mg, three times a day, d2-15 in each cycle, and icotinib 125mg,three times a day, since the last cycle until disease progression
Study NCT03151161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Icotinib
Description: Single drug: Icotinib 125mg, three times a day, continuous until disease progression.
Study NCT00103116 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous dendritic cell cancer vaccine
Description: Dendritic cells made from white blood cells obtained through out-patient leukapheresis procedure.~Vaccine given by injection under the skin in the front, upper thigh. Two vaccine injections total, given one month a part.
Study NCT02498418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Tablets, generic formulation of the brand product.
Study NCT02498418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xifaxan®
Description: Tablets, brand product.
Study NCT02498418 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: Placebo tablets in the same image of the generic rifaximin. Has no active ingredient.
Study NCT01026103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tri Staple Technology stapler
Description: This is a single arm study.
Study NCT04494152 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic echocardiography
Description: Standard Point-of-Care echocardiographic examination in the intensive care unit.
Study NCT00567242 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Word-finding with intention component
Description: Word-finding trials (picture-naming) with intention manipulation (initiating word-finding trials with a complex left-hand movement). 8 (or more) baseline sessions over 4 days followed by 30 treatment sessions (2 sessions/day, 5 days/week for 3 weeks).
Study NCT00567242 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Word-finding with no intention component
Description: Word-finding trials with no intention manipulation. 8 (or more) baseline sessions in 4 days followed by 30 treatment sessions (2 sessions/day, 5 days/week for 3 weeks).
Study NCT03348254 — intervention group
Intervention type: DRUG
Intervention: Single shot antibiotic prophylaxis
Description: single shot preoperative antibiotic prophylaxis
Study NCT03348254 — intervention group
Intervention type: DRUG
Intervention: Multiple shot antibiotic prophylaxis
Description: Multiple shot perioperative antibiotic prophylaxis
Study NCT01324492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Study NCT03347773 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ReGen 18%
Description: ReGen 18% is a kind of oral nutritional supplement, designed for patients under regular hemodialysis. One can of ReGen 18% contains 237ml, 425 Kcal, 19.1g protein, 22.7g lipid and 37.9g carbohydrate.
Study NCT03053908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Actigraphy
Description: Recording of sleep/wake cycle and TST by actigraphy to be completed at home by subject over 7 days
Study NCT03053908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nocturnal Polysomnograpahy (NPSG)
Description: N1 habituation and N2 data collection
Study NCT01004484 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A probiotic yogurt with inulin
Description: A 4 oz. cup with a probiotic yogurt containing Streptococcus thermophilus and Lactobacillus bulgaricus (at least 1x10\^8 cfu/g); the probiotic bacteria Bifidobacterium lactis (Bb12) (5x10\^7 cfu/g; 5x10\^9 cfu/serving) and Inulin (3gr/serving), once daily.
Study NCT01580735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 197
Description: ARQ 197:360 mg bid (CYP2C19 EM) or 240mg bid (CYP2C19 PM)~erlotinib: 150 mg qd
Study NCT00862225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
Study NCT00862225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadin
Description: Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.